ResearcherJohns Hopkins UniversityActive in the last 2 years
Janelle Marie Montagne
Matched on ORCID iD 0000-0002-8113-1373; OpenAlex author ID A5046687685. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 34
2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers
Papers 7
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
- Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
- A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
- CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. Co-author DOI 10.1016/j.isci.2024.111569↗
- Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic resp… Co-author DOI 10.1101/2024.09.22.613714↗
- Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. Co-author DOI 10.4049/jimmunol.2200660↗
- Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
Closest collaborators
The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elana Judith Fertig · 7 shared papers, 2022–2026 · strength 1.33
- Paper Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. DOI 10.4049/jimmunol.2200660↗
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Elizabeth M. Jaffee · 7 shared papers, 2022–2026 · strength 1.33
- Paper Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. DOI 10.4049/jimmunol.2200660↗
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Robert A. Anders · 6 shared papers, 2022–2026 · strength 1.02
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Won Jin Ho · 5 shared papers, 2024–2026 · strength 0.92
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Hao Wang · 4 shared papers, 2022–2026 · strength 0.71
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Luciane Tsukamoto Kagohara · 4 shared papers, 2024–2026 · strength 0.69
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Paper CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer cl… DOI 10.1016/j.isci.2024.111569↗
- Jae Woo Lee · 3 shared papers, 2026 · strength 0.61
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Katherine M. Bever · 3 shared papers, 2026 · strength 0.61
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Amanda L. Huff · 3 shared papers, 2026 · strength 0.61
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Mark M. Yarchoan · 3 shared papers, 2024–2026 · strength 0.52
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Paper Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancrea… DOI 10.1101/2024.09.22.613714↗
- Jacob T. Mitchell · 3 shared papers, 2022–2026 · strength 0.50
- Paper A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells … DOI 10.1158/2326-6066.cir-25-0545↗
- Paper CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer cl… DOI 10.1016/j.isci.2024.111569↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Thatcher Ross Heumann · 3 shared papers, 2022–2026 · strength 0.48
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Daniel A. Laheru · 3 shared papers, 2022–2026 · strength 0.48
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Lei Zheng · 3 shared papers, 2022–2025 · strength 0.42
- Paper CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer cl… DOI 10.1016/j.isci.2024.111569↗
- Paper Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancrea… DOI 10.1101/2024.09.22.613714↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Saurav Daniel Haldar · 2 shared papers, 2026 · strength 0.38
- Marina Baretti · 2 shared papers, 2026 · strength 0.38
- Neeha Zaidi · 2 shared papers, 2026 · strength 0.38
- Nilofer Saba Azad · 2 shared papers, 2026 · strength 0.38
- Dimitrios N. Sidiropoulos · 2 shared papers, 2024–2025 · strength 0.31
- Paper CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer cl… DOI 10.1016/j.isci.2024.111569↗
- Paper Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancrea… DOI 10.1101/2024.09.22.613714↗
- Jacquelyn W. Zimmerman · 2 shared papers, 2022–2025 · strength 0.27
- Paper CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer cl… DOI 10.1016/j.isci.2024.111569↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Dung Thi Le · 1 shared paper, 2026 · strength 0.23
- Eric Scott Christenson · 1 shared paper, 2025 · strength 0.17
- Yao Xu · 1 shared paper, 2025 · strength 0.17
- Ashani T. Weeraratna · 1 shared paper, 2024 · strength 0.15
- Ashley L. Kiemen · 1 shared paper, 2024 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.